Want to see FULC full AI Analyst Report?
Fulcrum Therapeutics (FULC) Stock Statistics & Valuation Metrics
Total Valuation
Fulcrum Therapeutics has a market cap or net worth of $287.64M. The enterprise value is -$34.44M.
- Market Cap
- $287.64M
- Enterprise Value
- -$34.44M
Share Statistics
Fulcrum Therapeutics has 76,297,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 76,297,260
- Owned by Insiders
- 18.23%
- Owned by Institutions
- 26.32%
Financial Efficiency
Fulcrum Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -23.84%.
- Return on Equity (ROE)
- -0.21
- Return on Assets (ROA)
- -0.20
- Return on Invested Capital (ROIC)
- -23.84%
- Return on Capital Employed (ROCE)
- -0.24
- Revenue Per Employee
- 0
- Profits Per Employee
- -8.32M
- Employee Count
- 9
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Fulcrum Therapeutics is -3.04. Fulcrum Therapeutics’s PEG ratio is -8.03.
- PE Ratio
- -3.04
- PS Ratio
- 0.00
- PB Ratio
- 0.90
- Price to FCF
- -4.25
- Price to Operating Cash Flow
- -4.27
- PEG Ratio
- -8.03
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 0 and earned -74.88M in profits. Earnings per share was -1.18.
- Revenue
- 0
- Gross Profit
- -1.39M
- Operating Income
- -84.77M
- Pretax Income
- -74.88M
- Net Income
- -74.88M
- EBITDA
- -73.49M
- Earnings Per Share (EPS)
- -1.18
Cash Flow
In the last 12 months, operating cash flow was -65.78M and capital expenditures -365,000, giving a free cash flow of -66.14M billion.
- Operating Cash Flow
- -65.78M
- Free Cash Flow
- -66.14M
- Free Cash Flow per Share
- -0.87
Dividends & Yields
Fulcrum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.59%
- Earnings Yield
- -30.33%
Stock Price Statistics
- Beta
- 1.91
- 52-Week Price Change
- -53.24%
- 50-Day Moving Average
- 3.75
- 200-Day Moving Average
- 5.71
- Relative Strength Index (RSI)
- 46.45
- Average Volume (3m)
- 1.50M
Important Dates
Fulcrum Therapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Fulcrum Therapeutics as a current ratio of 27.40, with Debt / Equity ratio of 1.85%
- Current Ratio
- 27.40
- Quick Ratio
- 27.40
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 2.60
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Fulcrum Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Fulcrum Therapeutics EV to EBITDA ratio is -3.06, with an EV/FCF ratio of -3.59.
- EV to Sales
- 0.00
- EV to EBITDA
- -3.06
- EV to Free Cash Flow
- -3.59
- EV to Operating Cash Flow
- -3.61
Balance Sheet
Fulcrum Therapeutics has $318.84M in cash and marketable securities with $5.28M in debt, giving a net cash position of $313.56M billion.
- Cash & Marketable Securities
- $318.84M
- Total Debt
- $5.28M
- Net Cash
- $313.56M
- Net Cash Per Share
- $4.11
- Tangible Book Value Per Share
- $4.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Fulcrum Therapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
- Price Target
- $3.00
- Price Target Upside
- 18.48% Downside
- Analyst Consensus
- Moderate Sell
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 0.04%
Scores
- Smart Score
- 1
- AI Score
- 51
